Two new life science venture capital funds launched recently with $500m to invest in biopharmaceutical and genomics firms, showing that funding for early-stage companies continues to be an attractive investment space, despite the slowdown in initial public offerings – one of two major exits for VC investors.
The new venture capital firm Pivotal bioVenture Partners in San Francisco has launched with $300m from a single limited partner – Hong Kong-based business conglomerate and investor Nan Fung Group – to back preclinical and Phase I drug developers in the US and Europe
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?